Polyclonal Rabbit LAMA2 Antibody
- Known as:
- Polyclonal Rabbit LAMA2 Antibody
- Catalog number:
- KA1936
- Product Quantity:
- 100ul
- Category:
- -
- Supplier:
- KareBay
- Gene target:
- Polyclonal Rabbit LAMA2 Antibody
Related genes to: Polyclonal Rabbit LAMA2 Antibody
- Gene:
- LAMA2 NIH gene
- Name:
- laminin subunit alpha 2
- Previous symbol:
- LAMM
- Synonyms:
- -
- Chromosome:
- 6q22.33
- Locus Type:
- gene with protein product
- Date approved:
- 1992-05-06
- Date modifiied:
- 2019-04-23
Related products to: Polyclonal Rabbit LAMA2 Antibody
Related articles to: Polyclonal Rabbit LAMA2 Antibody
- To compare the performance of a novel method for identifying candidate gene-environment interaction loci, Scalable Cauchy Aggregate test using Multiple Phenotypes to test Interactions (SCAMPI) (doi:10.1101/2024.09.10.612314v1), to widely used existing methods, Levene's test and conditional quantile regression (CQR). The 3 methods were evaluated for refractive error, a trait known to exhibit widespread gene-environment interaction effects. - Source: PubMed
Publication date: 2026/05/05
He XiTerry LouiseGuggenheim Jeremy A - LAMA2-related congenital muscular dystrophy (CMD), the most common form of CMD, is characterized by very early-onset muscle weakness, trunk instability, neuromuscular scoliosis, and progressive respiratory failure. The effectiveness of trunk bracing in neuromuscular scoliosis is controversial. The aim of this study was to investigate the effects of trunk bracing on spinal alignment, motor function, and pulmonary parameters in a patient diagnosed with LAMA2-related CMD. A 6-year-old female patient with a homozygous LAMA2 deletion and 37° left thoracolumbar scoliosis was recommended to use a thoracolumbar-sacral orthosis (TLSO) while sitting. Assessments were performed at baseline, on day 20, and at week 6. Spinal asymmetry during sitting, Motor Function Measure (MFM), Expanded Hammersmith Functional Motor Scale (HFMSE), Trunk Control Measurement Scale (TCMS), and spirometry-based respiratory function tests (Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC) were evaluated. The patient continued with a standard physical therapy program twice a week. The average daily corset usage time was 4 hours. The MFM score increased from 27 to 42 points, and the HFMSE score increased from 5 to 9 points. An increase was observed in pulmonary parameters (FEV1: 39-54%; FVC: 40-64%). TCMS scores remained stable (7-7-7 points). No side effects were reported. The use of a trunk brace may have positive effects on sitting posture, motor performance, and pulmonary function in LAMA2-related congenital muscular dystrophy. - Source: PubMed
Uğur FatmaAydin Yağcioğlu GüllüBulut NumanGürbüz İpekTunca Öznur - Intramuscular fat (IMF) deposition is regulated by fibro/adipogenic progenitors (FAPs), which possess bipotent differentiation capacity toward adipocytes or collagen-producing fibroblasts. Dysregulation of this process leads to excessive fibrosis or insufficient adipogenesis. However, the molecular mechanisms governing FAP proliferation and lineage commitment remain unclear. Here, we identified laminin α2 (LAMA2) as an autocrine extracellular matrix protein enriched in FAPs based on single-nucleus RNA sequencing. Functional analyses demonstrated that LAMA2 promotes FAP proliferation and adipogenic differentiation while inhibiting fibrogenesis. Mechanistically, LAMA2 interacts with integrin β1 (ITGβ1) to activate focal adhesion kinase (FAK) signaling, and elevation of p-FAK at Tyr397 was essential for coordinating cell expansion and adipogenic commitment. Inhibition of FAK abrogated the promotion of LAMA2 on FAP proliferation and differentiation. Our study identifies LAMA2 as a key regulator of FAPs that modulates intramuscular fat deposition and fibrosis, representing a promising target for improving livestock meat quality. - Source: PubMed
Publication date: 2026/06/10
Li AnHu HanzhuoLi XinmiaoZhou ZiliShama GagaFan YuanZhang MeihongYue BinglingXiong XianrongLin YaqiuLi JianXiong Yan - - Source: PubMed
Publication date: 2026/06/08
Khan HamedRehman AbdulAbubakar Hazrat - Carrier screening is a long-standing genetic testing process offered to at-risk couples, with or without a family history, who might have pregnancies affected by an autosomal recessive (AR) or X-linked (XL) disorder. A total of 276 unrelated individuals, initially referred for rare disorder screening by clinicians, were enrolled in this study and tested by Exome sequencing (ES). Expanded carrier screening (ECS) was performed for 176 disorders that met the inclusion criteria of the ACMG and ACOG. Genes with single nucleotide variants (SNVs) identified with a carrier rate > 1% for AR disorders included HBB, CFTR, PMM2, NPHS2, GJB2, ACADM, ALDOB, MEFV, MKS1, NEB, PAH, ATM, CPT2, CYP21A2, AGXT, BBS1, CAPN3, COL4A4, DHCR7, GAA, IVD, LAMA2, SLC22A5, SLC26A4, USH2A. For XL disorders, variants were detected in the RS1 gene. ECS offers a wealth of information about SNVs related to AR and XL disorders in specified populations. The information obtained from ECS provides multiple advantages: (a) it identifies the most prominent risks in health care in a given population and contributes to the prevention of genetic disorders, (b) it enriches available databases with pathogenic or likely pathogenic SNVs, and (c) it records novel targets for molecular clinical genetic testing. - Source: PubMed
Publication date: 2026/05/29
Kostoulas CharilaosSesse AthanasiaBouba IoannaNajdecki RobertKonitsiotis SpyridonMarkoula SofiaGeorgiou Ioannis